American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

GERON CORP

$1.13 -3.42% NASDAQ: GERN · 15-min delayed

FOSTER CITY, California
Public · NASDAQ: GERN
258 employees
Founded 1990

Visit website Follow

$750.6MMarket cap

$237.0KRevenue · FY2023

-$83.5MNet income

258Employees

GERNNASDAQ

1996IPO

About GERON CORP

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Founded: 1990
Type: Public · NASDAQ: GERN
Employees: 258
IPO date: Jul 31, 1996
Headquarters: 919 EAST HILLSDALE BOULEVARD
FOSTER CITY, California 94404
Phone: (650) 473-7700
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: GERN Nasdaq
SEC CIK: 886744
EIN: 752287752
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow GERON CORP and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2023: $237.0K
Net income: -$83.5M
Total assets: $570.5M
Market cap: $750.6M
Operating margin: -37.3%
Net margin: -45.4%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

FY2021

FY2022

FY2023

FY2024

FY2025

Revenue Net income

FY 2025

Financial statements

Income statement

Revenue: $183.9M
Operating expenses: $252.5M
Operating income: -$68.6M
Income tax: $75.0K
Net income: -$83.5M
EPS (basic): $-0.13
EPS (diluted): $-0.13

Balance sheet

Total assets: $570.5M
Current assets: $520.3M
Total liabilities: $344.7M
Current liabilities: $111.5M
Shareholders’ equity: $225.9M

Cash flow

Operating cash flow: -$111.0M
Investing cash flow: $107.2M
Financing cash flow: $2.3M
Net cash flow: -$1.4M

Statements via Polygon.io (SEC filings)

NASDAQ: GERN

$1.13 -3.42%

15-minute delayed · data by Polygon.io

Past year

$1.07 $1.95

52-week range

Market cap: $750.6M
EPS (diluted): $-0.13
Shares outstanding: 664.2M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jul 31, 1996

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

Reported a net loss of $83.5M in FY2023.
Revenue grew 13100% from FY2021 to FY2025.
Trading 42% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.